Alexo Therapeutics Ltd.
951 Gateway Blvd, Suite 201
South San Francisco
5 articles with Alexo Therapeutics Ltd.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Alexo Therapeutics Presents Preclinical Data Demonstrating that ALX148 Bridges Innate and Adaptive Immunity to Enhance Antitumor Immune Response at the 59th Annual ASH Meeting
Data from the oral presentation at the 59th American Society of Hematology Annual Meeting (ASH) held in Atlanta, Georgia demonstrate that ALX148 triggers a broad antitumor response by bridging innate and adaptive immunity.
Alexo Therapeutics Presents Preliminary Results From ALX148 Phase I Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Preliminary results from the single agent portion of the trial (NCT03013218) showed that ALX148 is generally well tolerated in patients with advanced malignancy, with no dose-dependent impact on normal blood cells.
Alexo To Present ALX148 Clinical Data At The 32nd Annual Meeting Of The Society For Immunotherapy Of Cancer (SITC)
Alexo Announces Initiation Of Phase I Clinical Trial Of ALX148 For The Treatment Of Advanced Solid Tumors And Lymphoma